SHAREHOLDER ALERT: Investigation on Behalf of Alcobra, Ltd. Investors Announced by Law Offices of Howard G. Smith

Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Alcobra, Ltd. (“Alcobra” or the “Company”) (NASDAQ:ADHD). The investigation concerns possible violations of federal securities laws and allegations that the Company misrepresented its operations and financial prospects. Alcobra is a biopharmaceutical company focused on the development and commercialization of proprietary drug candidates, including MDX for the treatment of attention deficit hyperactivity disorder (ADHD).

On October 6, 2014, the Company announced that the topline results from its Phase III study of MDX in Adult ADHD demonstrated a statistically significant improvement in ADHD symptoms. Then, on October 22, 2014, Alcobra announced that the MDX Phase III study, in fact, did not demonstrate a statistically significant improvement in patient symptoms, stating in relevant part: “While a complete ITT analysis by ADHD subtypes is still ongoing…the magnitude of symptom improvement appears to be similar in all subtypes, and the Predominantly-Inattentive ADHD (PI-ADHD) subtype alone did not produce a statistically significant outcome.”

On November 17, 2014, Alcobra announced that the Company plans to meet with the FDA and launch a second adult Phase III study in 2015. According to the Company, Alcobra is “currently evaluating changes to the design and monitoring of the second trial to control the unusually high placebo response and wide response variability observed in the first Phase III study.” Following this news, Alcobra shares declined 6%, to a closing price of $3.24 per share on November 18, 2014, on unusually heavy volume.

If you purchased Alcobra shares between March 28, 2014 and November 14, 2014, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.